GSK

@GSK · London, UK · joined 21 Apr 2007

We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://t.co/NdSNH7YPuK

233 678Followers

698Following

14 946Posts total

20.3KViews on collected posts

Son gönderiler

GSK@GSK4 Sep

#Media #Investors Climate change is one of the greatest threats to human health, and its impact on patients with respiratory health conditions should not be underestimated. Through advances in sustainable respiratory care, we’re making progress towards our environmental goals. ht 2.2K views · 4 likes · 2 reposts · 2 replies Open on X →

GSK@GSK1 Sep

#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII. Learn more: https://t.co/V8LrcARV4L https://t.co/bAooFkPeGM 3.6K views · 13 likes · 3 reposts · 2 replies Open on X →

GSK@GSK24 Aug

@GSK Hãy tiếp tục phát triển và đưa điều tốt đẹp đấy đến với Việt Nam chúng tôi. Cảm ơn 98 views · 0 likes · 0 reposts · 0 replies Open on X →

GSK@GSK24 Aug

@GSK グローバル最速みたいで、GSK開発チームにリスペクトです！ 108 views · 0 likes · 0 reposts · 0 replies Open on X →

GSK@GSK24 Aug

@GSK This is very good news; I hope we can get this treatment in Iraq. 87 views · 0 likes · 0 reposts · 0 replies Open on X →

GSK@GSK24 Aug

#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB), marking an important milestone in liver disease innovation. CHB remains a leading cause of liver cancer worldwide. This approval reflects 6.8K views · 60 likes · 8 reposts · 5 replies Open on X →

GSK@GSK24 Aug

#News for #Investors and #Media: Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: https://t.co/ZODs1nnQGb https://t.co/p3Dx7NihnO 4.1K views · 12 likes · 1 reposts · 0 replies Open on X →

GSK@GSK29 Jul

#News for #Investors and #Media: At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, @ViiVHC. Find out more: https://t.co/aU7XA3wZ41 https:/ 3.3K views · 14 likes · 1 reposts · 0 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 7 gönderi, 100K–1M takipçi aralığıyla yan yana. hem erişimde hem etkileşimde benzerlerinin altında.

Medyan görüntülenme2 155bu hesap5 983100K–1M için medyan

Erişim, %0.92%bu hesap1.49%100K–1M için medyan

Etkileşim, %0.32%bu hesap0.93%100K–1M için medyan

Ölçüt	Bu hesap	100K–1M için medyan	Oran
Gönderi başına medyan görüntülenme	2 155	5 983	0.36×
Erişim (görüntülenme ÷ takipçi)	0.92%	1.49%	0.62×
Etkileşim oranı	0.32%	0.93%	0.34×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.3K29 Jul

4.1K24 Aug

6.8K

108

3.6K1 Sep

2.2K4 Sep

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.45%29 Jul

0.32%24 Aug

1.11%

0.00%

0.53%1 Sep

0.37%4 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.

What the audience does

Likes72.0%103 in total

Reposts10.5%15 in total

Replies6.3%9 in total

Quotes2.8%4 in total

Bookmarks8.4%12 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Son gönderiler

Aynı büyüklükteki hesaplara karşı

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Benzer hesaplar